Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Caribou Biosciences, Inc.NASDAQ: CRBU

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 95.86M shares rose 3.4% year over year, in line with the +3.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +3.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
95.86M+1.4% QoQ
Last fiscal yearDec 2025
93.39M+3.4% YoY
LTMMar 2026
94.18M+3.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year+3.4%——
3-year CAGR+15.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
93.39M USD
Year-over-year change
+3.4%
4-year CAGR
+11.6%

Weighted Avg Shares (Diluted) vs competitors

How CRBU compares with its peers on the latest reported figures

  • CRBU's LTM Mar 2026 weighted avg shares (diluted) of 94.18M shares is the 5th highest of the 11 companies compared; the peer median is 69.52M shares.
  • Its year-over-year change of +3.6% is the 6th highest of 11, against a peer median of +5.4%.
  • Over three fiscal years its annual growth of +15.4% compares with a peer median of +15.4%.
CRBU Competitors Peer median
Weighted Avg Shares (Diluted) for CRBU and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 202621.77M +1.1%+0.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
Peer median (excluding CRBU) 69.52M+5.4%+15.4%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.